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Abstract Multiple sclerosis (MS) is a chronic, inflamma-
tory, autoimmune disease of the central nervous system,
and is an important cause of disability in young adults. In
genetically susceptible individuals, several environmental
factors may play a partial role in the pathogenesis of MS.
Some studies suggests that high-salt diet ([5 g/day) may
contribute to the MS and other autoimmune disease
development through the induction of pathogenic Th17
cells and pro-inflammatory cytokines in both humans and
mice. However, the precise mechanisms of pro-inflamma-
tory effect of sodium chloride intake are not yet explained.
The purpose of this review was to discuss the present state
of knowledge on the potential role of environmental and
dietary factors, particularly sodium chloride on the devel-
opment and course of MS.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory,
autoimmune disease of the central nervous system (CNS),
and is a major cause of disability in young adults [1]. In
genetically susceptible individuals, environmental factors
play a significant partial role in the pathogenesis of MS [2].
Numerous studies examined the influence of environmental
factors, such as Epstein–Barr infection [3–5], vitamin D
levels [6–11], smoking [12, 13], obesity [14], sunlight
exposure [15, 16], and geographic variation, on MS
[17, 18].
Methodology
All quotable references were searched using Pubmed and
Google scholar between March and May 2016. References
that allowed free access to full text by the Medical
University of Silesia were retrieved and read. The oldest
publications were retrieved from the Medical University of
Silesia Library. One reviewer performed literature searches
and two other researchers independently screened the
articles. All disagreements were discussed and resolved by
the authors or in consultation with other experts. Infor-
mation used in our review was evaluated using evidence-
based medicine. Inclusion criteria for the articles were:
original papers, systematic reviews, systematic summaries,
and meta-analysis. We excluded publications written in
foreign languages, such as Spanish, German, or Russian.
Keywords used for literature searches were as follows:
‘‘multiple sclerosis’’, ‘‘MS’’, ‘‘sodium’’, ‘‘sodium chlo-
ride’’, ‘‘autoimmunity’’, ‘‘diet’’, and ‘‘VGSCs’’. All key-
words were in accordance with the MeSH terms. To
identify the appropriate publications, we searched Pubmed
and Google scholar using combinations of keywords in the
following order: ‘‘MS and diet’’, ‘‘MS and salt intake’’,
‘‘MS and environmental factors,’’ and ‘‘MS and VGSCs’’.
After reading titles and abstracts, some articles from each
combination of keywords were excluded. Most of the
excluded articles were in a foreign language. The
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comprehensive literature search identified 907 articles that
were relevant for our review. Titles, abstracts, or full
articles were reviewed to determine whether each search
result matched our selection criteria. We also reviewed the
references of the selected original papers and review arti-
cles found by our search for additional papers relevant to
our review. Only high-quality publications from the last
decades were included. In addition, 306 articles were
retrieved from the Medical University of Silesia Library.
Of these 306 articles, we eliminated those that were too
general in scope for our review.
Environmental factors influencing MS
Although some studies confirmed the link between a previous
infection with Epstein–Barr virus (EBV) and the development
of multiple sclerosis [3–5, 19–21], the involvement of EBV in
the etiology of MS is unclear. However, certain viral infec-
tions likely increase susceptibility to MS [22]. Sero-epi-
demiological studies have demonstrated that almost 100% of
adult MS patients are infected with EBV [19]. Late childhood
infection of EBV is proposed to be the serious risk factor for
the disease. Moreover, there is a strong EBV-specific CD8?
response in the blood of MS patients in the beginning of the
disease and the intensity decreases in the course of the illness
[2–5, 19, 20].
Low serum vitamin D levels are currently one of the
most studied environmental factors influencing the
development of MS. It has been shown that intake of food
rich in vitamin D significantly prevents the development
of MS or reduce activity of the disease [6–9, 16]. Nev-
ertheless, some authors did not report a protective role of
vitamin D supplementation for the development of MS
[9, 10].
Smoking is another possible factor for the development
of MS or might be responsible for worst prognosis of
course of the disease [13, 23]. Furthermore, smoking ces-
sation improved the prognosis in patients with MS.
Ramanujam et al. confirmed that the time to conversion to
secondary progressive MS (SPMS) decreases by 4.7% for
each additional year of smoking after the diagnosis in
patients with RRMS (acceleration factor 1.047; 95% CI
1.023–1.072; P \ 0.01) [13].
Obesity is a probable susceptibility factor for MS and
several other autoimmune diseases [24], but the relation-
ship between increased body mass index (BMI) and disease
activity has not been fully explained. There is no doubt that
obesity increases levels of pro-inflammatory cytokines and
is associated with low-grade inflammatory state [25]. There
are reports providing that RRMS activity is higher in obese
and overweight patients than in patients with normal BMI
undergoing IFN b treatment [14]. Moreover, Oliveira et al.
reported a positive relationship between elevated BMI and
disability in MS patients [26].
Ultraviolet radiation was proposed to be a significant
environmental factor influencing prevalence of the disease
[15]. Reduced risk of MS through exposure to sunlight is
probably mediated not only by increased production of
vitamin D in the skin, but also by the synthesis of anti-
inflammatory factors, such as IL-10, TNF-a, and Treg cells
[16]. Therefore, the latitude is nowadays considered to be
related with prevalence of MS. The disease is less frequent
near the equator and more frequent in northern countries
[18, 27]. Exceptions to this trend, namely, Sardinia, where
the prevalence of the disease is significantly higher [28],
and northern Scandinavia, with markedly low prevalence
[29], may be due to genetic and behavioral factors [18].
Influence of diet on MS
It seems that diet might have a significant relationship with
the inflammatory process of MS. Many studies have shown
that diet plays the role in the pathogenesis of MS
[17, 30–32]. Recent studies have provided the evidence for
a protective role of polyunsaturated fatty acids on the risk
of MS; however, there is no conclusive evidence for a
beneficial role of polyunsaturated fatty acid supplementa-
tion in patients with MS. Hoare et al. demonstrated that the
amount of omega-3 polyunsaturated fatty acids taken orally
is inversely proportional to the risk of demyelination in the
CNS [33]. Moreover, Khalili et al. found a strong corre-
lation between oral intake of lipoic acid (1.2 mg/day) and
decrease in the levels of pro-inflammatory cytokines,
including INF-c, ICAM-1, and anti-inflammatory cytoki-
nes, including TGF-b and IL-4, compared with placebo
group [35]. On the other hand, Torkildsen et al. showed
that consumption of omega-3 fatty acids used as
monotherapy or in combination with interferon beta-1a had
no beneficial effect on the disease compared to placebo
[34]. Retinoic acid (RA), an active metabolite of vitamin
A, revealed a strong immunosuppressive activity [36]. RA
has been shown to modulate the balance between Th1/Th2
and Th17/Treg cells and B cell function, contributing to
augmented tolerance and inhibited inflammatory response.
It also contributes to enhanced tolerance and reduction of
inflammatory effects [37]. Bitarafan et al. investigated the
impact of vitamin A on disease progression in MS patients.
The study evaluated the expanded disability status scale
(EDSS) and MS functional composite (MSFC). The results
showed that vitamin A improved MSFC in RRMS patients,
but did not affect EDSS, relapse rate, or active brain lesions
in MRI [38]. Ketogenic diet (high amount of fat, decreased
protein content, and very low carbohydrates) was shown as
potentially therapeutic in progressive forms of MS, which
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is especially relevant, because currently, there is no treat-
ment for progressive forms of the disease [39, 40]. Kim
et al. reported that ketogenic diet improved motor disability
and cognitive impairment in mice with experimental
autoimmune encephalomyelitis compared with mice on the
standard diet. Furthermore, a ketogenic diet reversed
structural brain lesions and reduced CNS inflammation and
oxidative stress [41]. On the other hand, it was reported
that creatine supplementation did not improve muscle
capacity or habitual fatigue in MS individuals [42] or that
restricted intake of animal fat (no more than 10–15 g/day)
caused remission of the disease in patients with RRMS
[43].
Polyphenols and carotenoids from vegetables, n-3
PUFA from fish, vitamins A, C, D, and E, thiol compounds,
such as lipoic acid, and oligoelements, such as selenium
and magnesium, have anti-oxidant properties [44, 45].
Th17 cells, which produce pro-inflammatory cytokines, are
increased, whereas Treg cells are decreased in MS, and
thus, the balance between Th17 and Treg cells is impaired
in this disease. Vitamin A and its active metabolites (all-
trans-retinoic acid and 9-cis-retinoic acid) modulate the
imbalance of Th17 and Treg cells and might be beneficial
to the prevention and treatment of MS [46]. Moreover, this
vitamin was proposed to have a beneficial effect during
interferon therapy and improved psychiatric outcomes for
anti-inflammatory mechanisms [37].
Sodium channels in MS
Voltage-gated sodium channels (VGSCs) are key media-
tors of action potential initiation and propagation in
excitable cells [47–49]. Their expression has also been
reported in cell types that are traditionally regarded as non-
excitable, including glia, human vascular endothelial cells,
human epidermal keratinocytes, and carcinoma cells,
where their role is less clear [50–55]. Aberrant functional
expression/activity of VGSCs has been identified as a
major contributing factor in a number of human patholo-
gies, including cardiac arrhythmia [55], epilepsy
[56, 57, 58], pain [59, 60], periodic paralysis [61, 62],
migraine [63], MS [64], and cancer [65]. VGSCs exist as
heteromeric membrane-bound protein complexes that typ-
ically consist of a single pore-forming a subunit in asso-
ciation with one or more b subunits [66, 67].
The mammalian sodium channels include ten members
(Nav1.1–Nav1.9 and Nax) encoded by genes SCN1A–
SCN11A. While substantial homology exists between the
isoforms, differences in amino acid sequence confer dis-
tinct voltage dependence, kinetic and pharmacological
properties on each of the isotypes [68, 69]. Data concerning
the location and function of each VGSCs subunit are
included in Table 1.
b subunits (b1–b4) combine in vivo with either b1 or b3
through non-covalent bonding and with either b2 or b4 via
a covalent bond [101–104]. Numerous studies have
revealed the presence of Nav1.1, Nav1.2, Nav1.3 [105],
Nav1.6 [106], and Nav1.5 [107] in rodent astrocytes.
Sodium channels in these glial cells are localized to the
plasma membrane, where they mediate sodium currents
[108]. The star-shaped glial cells situated in the CNS take
an essential part in the response of the CNS to injury,
including inflammation and degeneration in MS. Herzog
et al. have shown that VGSCs can contribute to axonal
injury in MS by providing a pathway for sustained sodium
influx that drives the Na?/Ca2? exchanger to import cal-
cium into axons [109]. Elevated calcium levels can activate
nitric oxide synthase and deleterious proteolytic enzymes
[109–112]. The harmful effects of nitric oxide on mito-
chondrial function include a reduction in adenosine
triphosphate (ATP) levels and an exhaustion of sodium–
potassium adenosine triphosphatase (Na?K?-ATPase),
hence compromising the axons’ capacity to maintain nor-
mal transmembrane sodium gradient. This action provides
a positive feedback loop that imports even more intracel-
lular calcium, thereby further enhancing the damage [113].
Consequently, these mechanisms lead to axonal injury and
further to disability (Fig. 1).
Numerous studies have shown that partial blockade of
voltage-gated sodium channels could result in neuroprotec-
tion in patients with MS [112]. Indeed, the axonal protection
has been demonstrated in animals with experimental
autoimmune encephalomyelitis (EAE) by means of the
sodium channel blocking drugs flecainide [114, 115], safi-
namide [115], phenytoin [116], and, recently, lamotrigine
[117]. Neuroprotection is emerging as a potentially impor-
tant strategy for preventing disability progression in MS
[118]. In contrast, some clinical studies do not support the
protective role of VGSC blockers in MS. Counihan et al.
studied 400 patients, 51 of whom received CBZ symp-
tomatic therapy (average duration of therapy was
27 months), and showed that the long term exposure to the
VGSC-blocking drug CBZ does not affect the long-term
disability and disease progression in MS patients, despite
studies in animals suggesting a neuroprotective role of
VGSC blockers [119]. Furthermore, using CSF neurofila-
ment (NfH) as a good surrogate marker of neurodegenera-
tion in MS, Gnanapavan et al. revealed no benefit of
lamotrigine in the prevention of axonal breakdown by
lowering NfH levels compared to the placebo arm [120].
The protective role of lamotrigine is also disputed by
Kapoor et al. [121], but it is premature to fully dismiss this
hypothesis.
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Sodium chloride intake and MS
High intake of sodium chloride is currently considered to
be a potentially important factor influencing the onset of
MS. Changes in eating habits that have occurred in recent
decades in developed countries may account for an
increase in incidence of MS and other autoimmune dis-
eases [122]. Today’s typical Western diet includes more
sodium chloride than it was in the past [123]. Therefore,
popular processed meals, such as ‘‘fast food’’, contain
approximately 100 times more sodium chloride than
homemade meals [124, 125]. Increased hypertonicity can
stimulate the immune system [126], and furthermore,
superior sodium chloride uptake can affect the innate
immune system [127].
Recent studies have demonstrated the importance of
interleukin-17 (IL-17)-induced CD4? Th17 cell population
in autoimmune diseases [128]. Kleinewietfield et al.
showed that the addition of a modest amount of NaCl
(40 mM) to a culture of differentiating Th17 cells caused a
roughly logarithmic augmentation of IL-17A in naı¨ve CD4
cells in vitro and this process was mediated by p38/MAPK,
NFAT5, and SGK [122]. Moreover, high-salt concentration
results in growth of pathogenic phenotype of Th17 cells
[122, 129, 130]. Thus, the change in eating habits that
includes a high amount of salt may contribute to the recent
increase in MS incidence through the induction of patho-
genic Th17 cells [122, 126, 128]. The Th17 cells induced
by high-salt concentration upregulate the production of
pro-inflammatory cytokines GM-CSF, TNFa, IL-2, IL-9,
several chemokines [131, 132], and CCR6 [133], which are
essential for the autoimmune function of Th17 cells.
Higher Na? concentration, such as that between 160 and
250 mM, in the interstitium and lymphoid tissue and sig-
nificantly lower concentration of Na? in plasma, approxi-
mately 140 mM, are likely to be the mechanism for
Table 1 Voltage-gated sodium channels (VGSCs)
Protein Human gene Location Function
(A) The a subunits
Nav1.1 SCN1A CNS, PNS, heart CBH, dementia [70], Dravet syndrome [71], epilepsy [71, 72]
Nav1.2 SCN2A CNS, PNS CBH, dementia [70], epilepsy [73, 74], autism [74]
Nav1.3 SCN3A CNS, PNS Diabetes [75], neuropathic pain [76–78]
Nav1.4 SCN4A Skeletal muscle, heart Brugada syndrome [79], myotonia, periodic paralysis [80]
Nav1.5 SCN5A Uninnervated skeletal muscle, heart,
brain
Breast cancer [81, 82], arrhythmia [83], Brugada syndrome [84],
angiogenic disorders [85]
Nav1.6 SCN8A CNS, PNS, heart Epilepsy [86], cervical cancer [87]
Nav1.7 SCN9A PNS, neuroendocrine cells, sensory
neurons
Angiogenic disorders [85], paroxysmal extreme pain disorder [88]
Nav1.8 SCN10A Sensory neurons Prostate cancer [89], cardiac arrhythmia [90], MS [90, 91]
Nav1.9 SCN11A Sensory neurons Congenital insensitivity [92], cold-aggravated pain [93]
Nax SCN6A,
SCN7A
Heart, uterus, skeletal muscle,
astrocytes, DRG
Atopic dermatitis [94], hypertension [95]
(B) The b subunits
b1 SCN1B Heart, skeletal muscle, CNS, glia, PNS Epilepsy [96], cardiac arrhythmia [97], cancer [98]
b1A(b1B) SCN1B Heart, skeletal muscle, adrenal gland,
PNS
Epilepsy [96]
b2 SCN2B CNS, PNS, heart, glia Altered pain response [59], MS [99]
b3 SCN3B CNS, adrenal gland, kidney, PNS Cancer [98]
b4 SCN4B Heart, skeletal muscle, CNS, PNS Huntington’s disease [100]
CNS central nervous system, MS multiple sclerosis, PNS peripheral nervous system, CBH chronic brain hypoperfusion
Fig. 1 Positive feedback loop of Na/Ca influx to the neuron cell with
a potential damaging effect in multiple sclerosis (VGSC voltage-gated
sodium channel, NO nitric oxide, ATP adenosine triphosphate,
Na?K?-ATPase sodium–potassium adenosine triphosphatase)
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decreasing the inflammatory response in the blood while
favoring immune activation in lymphoid tissues or with
migration of cells into tissue [127, 134]. Otherwise, diet
rich in salt can affect the severity of the disease.
Kleinewietfeld et al. showed that mice fed salty meals
developed deterioration of EAE, with an increase in Th17
cell number and augmented infiltration of Th17 cells into
the CNS [122]. Moreover, in an observational trial on 122
MS patients, Farez et al. demonstrated that the disease
exacerbation rate was 2.75-fold in participants with med-
ium salt intake (2–4.8 g/day) (95% CI 1.3–5.8) and 9.95-
fold in participants with high sodium intake (4.8 g/day or
more) (95% CI 1.4–11.2) compared with the low-intake
group (under 2 g/day) [135]. This finding may be due to the
fact that sodium concentration is tightly regulated within
narrow limits regardless of large variations in sodium
consumption, due to its importance in general metabolism
[136]. The renin–angiotensin–aldosterone system (RAAS),
which is a major regulator of blood pressure, also signifi-
cantly affects autoimmunity in many diseases which
include MS and its animal model—EAE. Han et al. showed
that peptides related to the RAAS are present in CNS
lesions of MS patients [137]. Sodium chloride, among
many other physiological effects, modulates the renin–an-
giotensin system [138]. Interestingly, the activation of
renin and angiotensin has been implicated in the patho-
genesis of EAE [139]. Furthermore, increases in systolic
blood pressure similar to those observed with high-salt
consumption have recently been shown to be associated
with the disruption of white matter integrity in young
normotensive individuals [140]. In addition, Platten et al.
demonstrated an increase in the expression of angiotensin
receptor 1 (AT1R) in lymph node cells, indicating that
AT1R is activated in antigen-specific T cells during the
peripheral immune response to autoantigens. In addition,
angiotensin II (AII) binding was augmented in Periodate–
Lysine–Paraformaldehyde (PLP)-activated CD4 ? T cells
and to a lesser extent in activated CD11b ? monocytes.
Immunization with PLP139–151 led to an induction of AII
in CD4 ? T cells, CD11b ? monocytes, and to an increase
in serum AII levels, demonstrating that the RAAS is acti-
vated in peripheral immune cells. Pretreatment of mice
immunized with PLP139–151 with the angiotensin con-
verting enzyme (ACE) inhibitor lisinopril {N2-[(S)-1-car-
boxy-3-phenylpropyl]-L-lysyl-L-proline} or the AT1R
antagonist candesartan (3-{[20-(2 H -tetrazol-5-yl)biphe-
nyl-4-yl]methyl}-2-ethoxy-3 H -benzo[d]imidazole-4-car-
boxylic acid) resulted in suppression of Th1 and Th17
cytokine release and up-regulation of immunosuppressive
cytokines, such as IL-10 and transforming growth factor-b
(TGF-b) [141]. Probable impact of high sodium diet on
immune functions in MS patients was presented in Fig. 2.
Hucke et al. revealed a multidirectional activity of
sodium chloride-rich diet in both humans and mice.
Sodium chloride-rich diet promotes CNS autoimmunity,
increases macrophage responses, skews the balance
towards a pro-inflammatory M1 phenotype in macro-
phages, alters MAPK signaling in macrophages, and
induces a pro-inflammatory phenotype in human mono-
cytes [142]. In addition, Yi et al. demonstrated that high-
salt intake promotes an increase in human serum mono-
cytes, which play a pivotal role in the development of
various immunological diseases [143]. Furthermore, Jo¨rg
et al. showed that a high-salt diet in the early phase of
neuroinflammation mainly acts on Th17 cells and is inde-
pendent of myeloid cells. This finding can help elucidate
the impact of a high-salt diet on the emergence and course
of autoimmune diseases [144]. Krementsov et al. demon-
strated an increase in blood–brain barrier permeability and
brain pathology in mice as a consequence of a high-salt
diet, but did not demonstrate augmentation of Th17 or Th1
responses. Moreover, this study showed that the effects of
dietary sodium on autoimmune neuroinflammation are sex-
specific, genetically dependent, and CNS-mediated [145].
Furthermore, Zhou et al. demonstrated that a short-term
increase in dietary salt intake could induce the expansion of
CD14??CD16? monocytes, as well as an increase in
monocyte platelet aggregates (MPAs), which might be the
cellular basis of high-salt-induced end organ inflammation
and potential thromboembolic risk, independent of changes
in blood pressure [146]. In addition, Hernandez et al.
reported that excess dietary sodium intake lowers
immunosuppressive actions of human and murine Foxp3?
Tregs in vitro and in vivo and is associated with increased
Treg IFNc secretion in vivo [147]. Data concerning the
immunological effects of sodium chloride intake are shown
in Table 2.
Fig. 2 Probable impact of high sodium diet on immune functions in
multiple sclerosis patients (CNS central nervous system, RAAS renin–
angiotensin–aldosterone system)
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In conclusion, recent reports have demonstrated a
potential pro-inflammatory role of excess sodium chloride
intake in the pathogenesis of autoimmune and neurode-
generative diseases, both in vitro and in vivo, although the
outcomes of these studies are not unanimous. Nevertheless,
the current knowledge suggests that a low-salt diet
(\5 g/day) might be beneficial in the prevention and
treatment of autoimmune diseases, including MS.
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